Acitretin for treatment of EGFR inhibitor-induced cutaneous toxic effects.
Pomerantz
Rebecca G
RG
Chirinos
Rodolfo E
RE
Falo
Louis D
LD
Geskin
Larisa J
LJ
D017255:Acitretin / Q000008:administration & dosage / Q000627:therapeutic use*; D000284:Administration, Oral; D003937:Diagnosis, Differential; D004334:Drug Administration Schedule; D003875:Drug Eruptions / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology / Q000473:pathology; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D000069347:Erlotinib Hydrochloride; D005260:Female; D006801:Humans; D007641:Keratolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011799:Quinazolines / Q000009:adverse effects*
D007641:Keratolytic Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors; D017255:Acitretin